This Core will provide cornprehensive and centralized statistical support to all components within the SPORE, and address explicit issues including statistical study design, data analysis and data management for preclinical and clinical studies.
The specific aims of this Core are to:
Aim 1 : To coordinate and manage statistical activities to ensure that all SPORE investigators have ready and dedicated access to biostatistical consultation, data analysis and reporting;
Aim 2 : To provide expertise in statistical design, planning and conduct of clinical trials and preclinical studies including data review, quality control and protocol compliance;
Aim 3 : To provide comprehensive support for data analysis including safety/toxicity/futility/efficacy monitoring, interim reviews of data, final analysis, interpretation and reporting;
Aim 4 : To coordinate data management activities in close collaboration with the Clinical Research Core. Centralized biostatistical support (a) facilitates continuation and efficient use of biostatistical services, (b) provides an opportunity for dynamic collaboration between biostatisticians and investigators in the design, conduct, analysis and interpretation of results for all projects, and (c) ensures the conduct of high-quality projects that incorporate from the design stage appropriate and state-of-the-art statistical methods. For all types of research data (human, mouse, cell line, etc), the core can execute planned analyses efficiently. The core has a dedicated and experienced team of biostatisticians devoted to this research effort, which can flexibly and efficiently shift from one project to the next. Core personnel will help the investigators design new studies and test new hypotheses that may arise by the interactions of related projects. Data management activities for all clinical studies (phase 1 trials for all projects) will be highly coordinated between the Biostatistics Core and the Clinical Research Core B to ensure appropriate data collection and sufficient quality control while maintaining efficiency in the conduct of these activities.

Public Health Relevance

This is a continuation of an existing and well-functioning Core that provides an essential infrastructure for close collaboration and interactions between biostatisticians and SPORE investigators. All SPORE projects will require substantial statistical support for preclinical experiments and clinical trials. The Core infrastructure will insure implementation of innovative and high-quality SPORE translational studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA126752-07
Application #
8547758
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
7
Fiscal Year
2013
Total Cost
$131,070
Indirect Cost
$66,822
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Heslop, Helen E; Brenner, Malcolm K (2018) Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther 26:1-2
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Velasquez, Mireya Paulina; Bonifant, Challice L; Gottschalk, Stephen (2018) Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131:30-38
Kalra, Mamta; Gerdemann, Ulrike; Luu, Jessica D et al. (2018) Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy :
Ngai, Ho; Tian, Gengwen; Courtney, Amy N et al. (2018) IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol 201:2141-2153
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Lyon, Deborah; Lapteva, Natasha; Gee, Adrian P (2018) Absence of Replication-Competent Retrovirus in Vectors, T Cell Products, and Patient Follow-Up Samples. Mol Ther 26:6-7
Su, Jianzhong; Huang, Yung-Hsin; Cui, Xiaodong et al. (2018) Homeobox oncogene activation by pan-cancer DNA hypermethylation. Genome Biol 19:108

Showing the most recent 10 out of 270 publications